Matches in SemOpenAlex for { <https://semopenalex.org/work/W3156559780> ?p ?o ?g. }
- W3156559780 endingPage "369" @default.
- W3156559780 startingPage "361" @default.
- W3156559780 abstract "Venetoclax-based regimens have expanded the therapeutic options for patients with chronic lymphocytic leukemia (CLL), frequently achieving remissions with undetectable measurable residual disease and facilitating time-limited treatment without chemotherapy. Although response rates are high and durable disease control is common, longer-term follow-up of patients with relapsed and refractory disease, especially in the presence of TP53 aberrations, demonstrates frequent disease resistance and progression. Although the understanding of venetoclax resistance remains incomplete, progressive disease is typified by oligoclonal leukemic populations with distinct resistance mechanisms, including BCL2 mutations, upregulation of alternative BCL2 family proteins, and genomic instability. Although most commonly observed in heavily pretreated patients with disease refractory to fludarabine and harboring complex karyotype, Richter transformation presents a distinct and challenging manifestation of venetoclax resistance. For patients with progressive CLL after venetoclax, treatment options include B-cell receptor pathway inhibitors, allogeneic stem cell transplantation, chimeric antigen receptor T cells, and venetoclax retreatment for those with disease relapsing after time-limited therapy. However, data to inform clinical decisions for these patients are limited. We review the biology of venetoclax resistance and outline an approach to the common clinical scenarios encountered after venetoclax-based therapy that will increasingly confront practicing clinicians." @default.
- W3156559780 created "2021-04-26" @default.
- W3156559780 creator A5034517642 @default.
- W3156559780 creator A5081326206 @default.
- W3156559780 creator A5090592945 @default.
- W3156559780 date "2021-04-19" @default.
- W3156559780 modified "2023-09-30" @default.
- W3156559780 title "How I treat chronic lymphocytic leukemia after venetoclax" @default.
- W3156559780 cites W1878424445 @default.
- W3156559780 cites W2009009231 @default.
- W3156559780 cites W2012189351 @default.
- W3156559780 cites W2047115666 @default.
- W3156559780 cites W2067064694 @default.
- W3156559780 cites W2091704908 @default.
- W3156559780 cites W2113278680 @default.
- W3156559780 cites W2115086589 @default.
- W3156559780 cites W2192121806 @default.
- W3156559780 cites W2339774970 @default.
- W3156559780 cites W2369297677 @default.
- W3156559780 cites W2573476619 @default.
- W3156559780 cites W2580500393 @default.
- W3156559780 cites W2605683323 @default.
- W3156559780 cites W2611243937 @default.
- W3156559780 cites W2735691291 @default.
- W3156559780 cites W2770821320 @default.
- W3156559780 cites W2773047201 @default.
- W3156559780 cites W2781558580 @default.
- W3156559780 cites W2787863642 @default.
- W3156559780 cites W2790385276 @default.
- W3156559780 cites W2792666902 @default.
- W3156559780 cites W2799716396 @default.
- W3156559780 cites W2800170673 @default.
- W3156559780 cites W2800186514 @default.
- W3156559780 cites W2808653175 @default.
- W3156559780 cites W2902460563 @default.
- W3156559780 cites W2902472954 @default.
- W3156559780 cites W2902484351 @default.
- W3156559780 cites W2902706178 @default.
- W3156559780 cites W2907015766 @default.
- W3156559780 cites W2907470861 @default.
- W3156559780 cites W2934305708 @default.
- W3156559780 cites W2940785776 @default.
- W3156559780 cites W2941780980 @default.
- W3156559780 cites W2946882253 @default.
- W3156559780 cites W2948118520 @default.
- W3156559780 cites W2948436219 @default.
- W3156559780 cites W2966190920 @default.
- W3156559780 cites W2974182987 @default.
- W3156559780 cites W2979710073 @default.
- W3156559780 cites W2984880931 @default.
- W3156559780 cites W2985062935 @default.
- W3156559780 cites W2990236854 @default.
- W3156559780 cites W2999901895 @default.
- W3156559780 cites W3000178175 @default.
- W3156559780 cites W3003410250 @default.
- W3156559780 cites W3007925874 @default.
- W3156559780 cites W3012414877 @default.
- W3156559780 cites W3012733259 @default.
- W3156559780 cites W3013074397 @default.
- W3156559780 cites W3013993168 @default.
- W3156559780 cites W3014195933 @default.
- W3156559780 cites W3016273290 @default.
- W3156559780 cites W3039488989 @default.
- W3156559780 cites W3080675765 @default.
- W3156559780 cites W3082097891 @default.
- W3156559780 cites W3082637551 @default.
- W3156559780 cites W3082899459 @default.
- W3156559780 cites W3088078660 @default.
- W3156559780 cites W3090791575 @default.
- W3156559780 cites W3095280492 @default.
- W3156559780 cites W3095661021 @default.
- W3156559780 cites W3095746683 @default.
- W3156559780 cites W3096836704 @default.
- W3156559780 cites W3097292094 @default.
- W3156559780 cites W3133932532 @default.
- W3156559780 cites W3134524629 @default.
- W3156559780 doi "https://doi.org/10.1182/blood.2020008502" @default.
- W3156559780 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33876212" @default.
- W3156559780 hasPublicationYear "2021" @default.
- W3156559780 type Work @default.
- W3156559780 sameAs 3156559780 @default.
- W3156559780 citedByCount "12" @default.
- W3156559780 countsByYear W31565597802021 @default.
- W3156559780 countsByYear W31565597802022 @default.
- W3156559780 countsByYear W31565597802023 @default.
- W3156559780 crossrefType "journal-article" @default.
- W3156559780 hasAuthorship W3156559780A5034517642 @default.
- W3156559780 hasAuthorship W3156559780A5081326206 @default.
- W3156559780 hasAuthorship W3156559780A5090592945 @default.
- W3156559780 hasBestOaLocation W31565597801 @default.
- W3156559780 hasConcept C126322002 @default.
- W3156559780 hasConcept C143998085 @default.
- W3156559780 hasConcept C203014093 @default.
- W3156559780 hasConcept C2776694085 @default.
- W3156559780 hasConcept C2776755627 @default.
- W3156559780 hasConcept C2777938653 @default.
- W3156559780 hasConcept C2778461978 @default.
- W3156559780 hasConcept C2779134260 @default.